

# Recurrent *Pseudomonas aeruginosa* Infection in Chronic Lung Diseases: Relapse or Reinfection?

Ho-Kee Yum, M.D.<sup>1</sup>, I-Nae Park, M.D.<sup>1</sup>, Bo-Mun Shin, M.D.<sup>2</sup> and Soo-Jeon Choi, M.D.<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, Inje University Seoul Paik Hospital, <sup>2</sup>Department of Laboratory Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea

**Background:** *Pseudomonas aeruginosa* infection is particularly associated with progressive and ultimately chronic recurrent respiratory infections in chronic obstructive pulmonary disease, bronchiectasis, chronic destroyed lung disease, and cystic fibrosis. Its treatment is also very complex because of drug resistance and recurrence.

**Methods:** Forty eight cultures from 18 patients with recurrent *P. aeruginosa* pneumonia from 1998 to 2002 were included in this study. Two or more pairs of sputum cultures were performed during 2 or more different periods of recurrences. The comparison of strains was made according to the phenotypic patterns of antibiotic resistance and chromosomal fingerprinting by pulsed field gel electrophoresis (PFGE) using the genomic DNA of *P. aeruginosa* from the sputum culture.

**Results:** Phenotypic patterns of antibiotic resistance of *P. aeruginosa* were not correlated with their prior antibiotic exposure. Fifteen of 18 patients (83.3%) had recurrent *P. aeruginosa* pneumonia caused by the strains with same PFGE pattern.

**Conclusion:** These data suggest that the most of the recurrent *P. aeruginosa* infections in chronic lung disease occurred due to the relapse of prior infections. Further investigations should be performed for assessing the molecular mechanisms of the persistent colonization and for determining how to eradicate clonal persistence of *P. aeruginosa*.

**Keywords:** *Pseudomonas aeruginosa*; Pneumonia; Electrophoresis, Gel, Pulsed-Field

**Address for correspondence:** Ho-Kee Yum, M.D.

Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, 9 Mareunnae-ro, Jung-gu, Seoul 100-030, Korea

**Phone:** 82-2-2270-0004, **Fax:** 82-2-2285-2286

**E-mail:** hoho@paik.ac.kr

**Received:** Mar. 5, 2014

**Revised:** Apr. 21, 2014

**Accepted:** Aug. 18, 2014

©It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

Copyright © 2014

The Korean Academy of Tuberculosis and Respiratory Diseases.

All rights reserved.

## Introduction

*Pseudomonas aeruginosa* is an aerobic gram-negative rod, which does not usually cause infection in the absence of impaired host defenses<sup>1</sup>. Recurrent *P. aeruginosa* infection is common in chronic pulmonary diseases like as chronic obstructive lung disease (COPD), bronchiectasis and chronic destroyed lung disease due to tuberculosis in Korea. It is not only resistant to a treatment with antibiotics, but also sometimes fatal in a destructive lung disease due to recurrent infections<sup>2-4</sup>.

Clinically, the same patterns of antibiotic susceptibility test of recurrent pneumonia after a couple of therapy months suggested that the pneumonia caused by *P. aeruginosa* would be due to predominantly to a reactivation of a previous strain (relapse) rather than to an exogenous reinfection<sup>3,4</sup>.


Moreover, this pseudomonas infection of lung is notorious

to a re-infection or relapse of diseases. Rello et al.<sup>5</sup> reported a relapse rate higher as 50% in mechanical ventilated patients with endobronchial intubation or tracheostomy patients in the intensive care unit (ICU). And Talon et al.<sup>6</sup> reported that endogenous sources of *P. aeruginosa* infection are associated with previous infections of patients in the ICU. Therefore, it is very important to determine whether recurrent *P. aeruginosa* pneumonia is a relapse or re-infection because it provides us with information how long to treat with antibiotics, how to manage the eradication of this troublesome organism and to decide the further research purposes.

Lots of phenotypic markers of *P. aeruginosa* were used such as pyocin production, pyocin susceptibility, serotyping, anti-biotyping and phage susceptibility<sup>7</sup>. However, there seems to be a poor correlation between *in vitro* antibiotic susceptibility testing and *in vivo* antibiotic efficacy. Recently, chromosomal fingerprinting was found to be useful to evaluate epidemiologic pattern<sup>8,9</sup>. The purpose of this study was to define whether recurrent *P. aeruginosa* pneumonia was caused by the relapse of previous strains or re-infection of new strains through the molecular typing of *P. aeruginosa*.

## Materials and Methods

Forty-eight episodes of 18 patients with recurrent *P. aeruginosa* pneumonia were included from 1999 through 2002. Two or more sets of sputum cultures were done during 2 or more different periods of recurrences. Several clinical data were evaluated and analyzed including underlying disease,




**Figure 1.** PFGE pattern of *Pseudomonas aeruginosa* strains isolated from patients with recurrent episodes of pneumonia (MW= molecular weight marker; A1, A2, and A3 are 3 different strains in each pneumonia episode in the same patient). PFGE: pulsed field gel electrophoresis.

comorbidities, antibiotic treatment, duration of diseases and susceptibility patterns.

A comparison was made between phenotypic patterns of antibiotic resistance and molecular typing based on pulsed field gel electrophoresis (PFGE) with genomic DNA of *P. aeruginosa* of sputum cultures.

### 1. Definition of pneumonia

The diagnosis of pneumonia was considered when new pulmonary infiltrates occurred with at least two of the following criteria: (1) fever >38°C; (2) leukocytosis >10,000 per mm<sup>3</sup>, and (3) purulent respiratory secretions. Antibiotic treatment of pneumonia was done by the American Thoracic Society (ATS) guideline, 2001<sup>10</sup>. Combination therapy was conducted with



**Figure 2.** The Dendrogram for percentage similarity among DNA profiles of isolates from cultured specimens.

two or more anti-pseudomonal antibiotics to which the *P. aeruginosa* was susceptible *in vitro*<sup>11</sup>. At least 2 weeks antibiotic therapy was done after the sputum showed positive culture. The clinical resolution was defined if the patient had complete resolution of all signs and symptoms of pneumonia along with radiologic improvement. Recurrent pneumonia was defined if it occurred after at least two months of complete treatment of the previous pneumonia without an evidence of a new extrapulmonary source of infection.

## 2. Microbiologic processing

*P. aeruginosa* strains from sputum cultures were collected and stored at  $-70^{\circ}\text{C}$ . Follow-up cultures were performed at each time of pneumonia recurrence. Antimicrobial susceptibility tests were determined using a commercial microdilution broth method, following the manufacturer's recommendations. The considered minimal inhibitory concentration interpretative standards for susceptibility categories were those given by the Korean guideline. Moderately susceptible and resistant bacteria were both regarded as resistant in this study.

## 3. Pulsed field gel electrophoresis

Genomic DNA for PFGE was prepared as previously reported<sup>12,13</sup>. Chromosomal DNA plugs were incubated with *Xba*I. Restriction fragments were separated with an orthogonal field alternation electrophoresis apparatus through 1% agarose gel for a 20 hours run at a constant voltage of 250 V (Figure 1). The pulse time was 20, 10, and 2 seconds for 3, 15, and 2 hours, respectively. PFGE chromosomal similarities of the fragment length patterns were compared between two strains using a dendrogram (Figure 2).

## 4. Statistical analysis

Variables were compared with t-test and one-way analysis of variance (ANOVA).

## Results

Demographic data and several predisposing factors of recurrent pneumonia were summarized of the included patients (Table 1). The mean duration of underlying disease was  $8.9 \pm 7.4$  years. *P. aeruginosa* was isolated in 48 episodes of the 18 patients with *P. aeruginosa* pneumonia. Eight of 18 patients developed a recurrence once; another 8 patients developed a recurrence twice and 2 patients developed a recurrence thrice. Bronchiectasis was the most common underlying disease in recurrent *P. aeruginosa* pneumonia in this study (11 of 18 patients).

**Table 1. Baseline clinical characteristics of patients with recurrent *Pseudomonas aeruginosa* pneumonia**

Variable	No.
Male:Female	6:12
Age, yr	59.2±12.3
Duration of underlying disease, yr	8.9±7.4
Number of hospitalizations*	5.17±1.89
WBC count in the peripheral blood	14,700±4,153
Underlying diseases	
COPD	3
Bronchiectasis	11
Destroyed lung due to tuberculosis	4

\*Number of hospitalizations means the number of admissions to the hospital due to respiratory infection since the underlying respiratory disease was diagnosed.

WBC: white blood cell; COPD: chronic obstructive lung disease.

The antibiotic resistance patterns of *P. aeruginosa* and PFGE patterns were summarized as well as their relationship with prior antibiotic exposure during the first episode of pneumonia (Table 2). Eighteen of 24 paired *P. aeruginosa* strains showed the same patterns of PFGE. Recurrent *P. aeruginosa* pneumonia occurred in 75% of the patients (Table 3). Twenty-two of 30 recurrent *P. aeruginosa* pneumonia cases (73.3%) were caused by the same PFGE patterns. The PFGE patterns were not statistically correlated with the intervals of pneumonia episodes, duration of underlying illness, and prior antibiotic usage.

Phenotypic patterns of antibiotic resistance of *P. aeruginosa* were not correlated with their prior antibiotic exposition. Number of episodes of recurrent pneumonia did not affect PFGE patterns statistically (Table 4).

The antibiotic susceptibility profiles of each pneumonia episode were compared with previous resistant patterns (Table 5). Only 7 pneumonic episodes are identical to their previous antibiotic susceptibility profiles. However, PFGE patterns were identical in 75% of pneumonic episodes. PFGE profiles are shown in Figures 1 and 2.

## Discussion

*P. aeruginosa* is one of the most common causes of pneumonia in structural lung diseases such as COPD, bronchiectasis, and destructive lung diseases. Chronic corticosteroid therapy (>10 mg of prednisone per day), broad-spectrum antibiotic therapy for more 7 days in the past month and malnutrition were high risk factors for a pseudomonal infection<sup>1</sup>.

It is very important to identify whether the resistant strains are recurred or relapsed. Previous studies have reported the

**Table 2.** Antibiotic resistance patterns of *Pseudomonas aeruginosa* strains and their relationship with prior antibiotic exposition and PFGE patterns

No.	Diagnosis	Episodes	Antibiotics resistance pattern	Prior antibiotics	PFGE pattern (%)
1	COPD	3	CTx (R-S)	Cep+AG	100
2	Bronchiectasis	2	Same as before (SAB)	Cep+AG	69
3	Bronchiectasis	3	SAB/CTX (S-R)	Cip+IMP	97, 95
4	Bronchiectasis	3	Cep, IMP, CTx, Amp (R-S)	Cep+Cip	100, 96
5	Bronchiectasis	2	Cep, Amp (S-R)	Cep+AG	75
6	Destroyed lung	3	SAB	Cip+Caz	100
7	Bronchiectasis	3	SAB/Cep, IMP, CIP, CTx, Caz	Cip+Mer	100
8	Destroyed lung	4	SAB/Amp, Cep (S-R)	Cep+Cip	100
9	Bronchiectasis	3	Cep, Ctx, Cip (S-R)	Cip+AG	100
10	Bronchiectasis	2	GM, Cip, Amk (S-R)	Caz+Cip	100
11	COPD	2	Cep, Amp, CTx (S-R)	Cip+IMP	100
12	Bronchiectasis	4	Cip, GM, Caz, Sxt, Mer (S-R)	Cep+AG	100, 95*
13	Bronchiectasis	2	SAB	Cep+Cip	100
14	Destroyed lung	3	SAB/Cep (R-S) and (S-R)	Cep+Cip+AG	100
15	COPD	3	Cep, IMP, CIP, CTx (S-R)	Cep+AG	100, 68
16	Destroyed lung	2	IMP, CTx (S-R), Sxt (R-S)	Cip+AG	78
17	Bronchiectasis	2	Cep, Sxt (S-R), IMP (R-S)	Cep+Caz	100
18	Bronchiectasis	2	Amp (S-R), Cep (R-S)	Cep+AG	100

\*Only one strain of *Pseudomonas aeruginosa* showed different PFGE patterns.

PFGE: pulsed field gel electrophoresis; COPD: chronic obstructive lung disease; CTx: cefotaxime; Cep: cephalosporines; AG: aminoglycosides; Cip: ciprofloxacin; Amp: ampicillin; Caz: ceftazidime; GM: gentamycin; Amk: amikacin; IMP: imipenem; Sxt: sulfomethoxazole; Mer: meropenem.

R-S means that the results of the susceptibility test were changed from resistant to sensitive to antibiotics and S-R means vice versa.

**Table 3.** PFGE patterns of *Pseudomonas aeruginosa* strains isolated from patients with recurrent episodes of pneumonia

	100% Matched PFGE pattern	
	(+)	(-)
Recurrent episodes of pneumonia (24 paired strains)	18 (75.0%)	6 (25.0%)
Interval between the episodes of pneumonia, mo	10.4±7.9	9.8±8.2
Duration of prior antibiotics, day	15.3±3.2	14.8±2.5

PFGE: pulsed field gel electrophoresis.

**Table 4.** PFGE pattern according to the number of recurrence episodes

No. of recurrence episodes	No. of patients	Total No. of pneumonia episodes	100% Matched PFGE	
			Yes	No
2	8	16	10 (62.5)	6 (37.5)
3	8	24	19 (79.2)	5 (20.8)
4	2	8	7 (87.5)	1 (12.5)
Total	18	48	36 (75.0)	12 (25.0)

Values are presented as number (%).

PFGE: pulsed field gel electrophoresis.

**Table 5.** Comparison between antibiotic phenotype and PFGE pattern in paired episodes of pneumonia

Antibiotic phenotype identical to the previous result	100% Matched PFGE		
	Yes	No	Total
Yes	2 (28.6)	5 (71.4)	7
No	12 (70.6)	5 (29.4)	17
Total	14 (58.3)	10 (41.7)	24

Values are presented as number (%).

PFGE: pulsed field gel electrophoresis.

incidence of recurrent pneumonia caused by *P. aeruginosa* in ICU showing a considerable disparity from 3% through 50%<sup>7,8</sup>.

Various conventional typing systems have been extensively used to study the epidemiology of *P. aeruginosa*. However, lots of phenotypic markers, such as pyocin production, pyocin susceptibility, serotyping, phage susceptibility, and antibiotyping were poorly correlated with bacterial strains<sup>14</sup>. And the reproducibility and accuracy of serotypes have been shown to be low. Recently, chromosomal fingerprintings are useful epidemiologic patterns<sup>15</sup>. Genomic fingerprinting by PFGE was found to be more sensitive than conventional typing methods such as serotyping, pyocin producing and phage typing for the differentiation of *P. aeruginosa* strains to identify between relapse and reinfection<sup>9-11</sup>. The molecular typing of the different strains isolated from patients with multiple episodes of pneumonia due to *P. aeruginosa* differentiates between relapse and reinfection.

Our data showed a poor correlation between prior antibiotic usage and PFGE patterns (Tables 2, 3). The number of pneumonia episodes did not affect the PFGE patterns. These data suggest that the most recurrent *P. aeruginosa* infection in a chronic lung disease occurs due to relapse of the prior infection. The most important mechanism of clinical recurrence is caused by the relapse of prior infected or colonized organisms.

Nevertheless, different molecular genotypes by restriction fragment length polymorphism patterns emerge from variants of the original after antibiotic treatment or are newly acquired strains. Mutations produce new strains that are resistant to anti-pseudomonal antibiotics by mechanisms that include a hyperproduction of chromosomal  $\beta$ -lactamase, an altered DNA gyrase, membrane changes reducing drug accumulation or mechanisms increasing the drug efflux. However, our data suggest that relapse is the most important mechanism of clinical recurrence<sup>6</sup>.

Niedermann et al.<sup>16</sup> showed the persistence of *P. aeruginosa* in the lower respiratory track of patients with chronic pulmonary diseases for approximately 57% of cultured sputum after antibiotic treatment.

The relapse mechanism is supposed to a persistent colonization in an anatomical destructive bronchial or lung pa-

renchymal focus, such as in bronchiectasis, destroyed lung due to tuberculosis sequele and so forth. And an incomplete or inadequate antibiotic therapy may attribute to a persistent colonization and recurrence as well. Therefore, the control focus should be based on persistent colonization or incomplete eradication of a *P. aeruginosa* infection.

Typically is *P. aeruginosa* nonmucoid at its first time of isolation, but after variable periods, often 1 or 2 years, it becomes mucoid strain and produces large amounts of an extracellular polysaccharide called alginate.

Damage to the epithelium, not to the normal epithelium and the structural proteins of lung facilitates the *P. aeruginosa* adherence. Activated neutrophils spill proteinase enzymes and oxygen radicals in cystic fibrosis or bronchiectatic airways.

Although this study has its limitations which were confirmed as the colonization after recovery of pseudomonal infection, the focus of control should be based on persistent colonization or incomplete eradication of *P. aeruginosa* infection. These results support the rationale of a long-term treatment with macrolide or fluoroquinolone antibiotics due the anti-inflammatory properties of macrolide antibiotics in a chronic pseudomonal respiratory tract infection.

In conclusion, we should determine whether the occurrence of relapse or re-infection to decide about the antibiotic treatment length and how to permanently eradicate. Also further research purposes should be determined on *P. aeruginosa* pneumonia in chronic structural destructive lung diseases and further investigation should be done about the molecular mechanism of persistent colonization and how to eradicate the colonial persistence of *P. aeruginosa*.

## Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

## Acknowledgements

This work was supported by a Grant from the Inje University, 2003.

## References

1. Dowling RB, Wilson R. *Pseudomonas aeruginosa* respiratory infections. Clin Pulm Med 1999;6:278-86.
2. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.

3. Moss RB, Wunderink RG. Strategies for drug therapy in treating *Pseudomonas* infection. *J Respir Dis* 1996;17:806-9.
4. Fink MP, Snyderman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. *Antimicrob Agents Chemother* 1994;38:547-57.
5. Rello J, Mariscal D, March F, Jubert P, Sanchez F, Valles J, et al. Recurrent *Pseudomonas aeruginosa* pneumonia in ventilated patients: relapse or reinfection? *Am J Respir Crit Care Med* 1998;157(3 Pt 1):912-6.
6. Talon D, Capellier G, Boillot A, Michel-Briand Y. Use of pulsed-field gel electrophoresis as an epidemiologic tool during an outbreak of *Pseudomonas aeruginosa* lung infections in an intensive care unit. *Intensive Care Med* 1995;21:996-1002.
7. Silver DR, Cohen IL, Weinberg PF. Recurrent *Pseudomonas aeruginosa* pneumonia in an intensive care unit. *Chest* 1992;101:194-8.
8. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to *Pseudomonas aeruginosa*. *Chest* 1996;109:1019-29.
9. Boukadida J, De Montalembert M, Lenoir G, Scheinmann P, Veron M, Berche P. Molecular epidemiology of chronic pulmonary colonisation by *Pseudomonas aeruginosa* in cystic fibrosis. *J Med Microbiol* 1993;38:29-33.
10. Doring G, Horz M, Ortelt J, Grupp H, Wolz C. Molecular epidemiology of *Pseudomonas aeruginosa* in an intensive care unit. *Epidemiol Infect* 1993;110:427-36.
11. Poh CL, Yeo CC, Tay L. Genome fingerprinting by pulsed-field gel electrophoresis and ribotyping to differentiate *Pseudomonas aeruginosa* serotype O11 strains. *Eur J Clin Microbiol Infect Dis* 1992;11:817-22.
12. Kirschke DL, Jones TF, Craig AS, Chu PS, Mayernick GG, Patel JA, et al. *Pseudomonas aeruginosa* and *Serratia marcescens* contamination associated with a manufacturing defect in bronchoscopes. *N Engl J Med* 2003;348:214-20.
13. Spencker FB, Haupt S, Claros MC, Walter S, Lietz T, Schille R, et al. Epidemiologic characterization of *Pseudomonas aeruginosa* in patients with cystic fibrosis. *Clin Microbiol Infect* 2000;6:600-7.
14. Poh CL, Yeo CC. Recent advances in typing of *Pseudomonas aeruginosa*. *J Hosp Infect* 1993;24:175-81.
15. Renders N, Romling Y, Verbrugh H, van Belkum A. Comparative typing of *Pseudomonas aeruginosa* by random amplification of polymorphic DNA or pulsed-field gel electrophoresis of DNA macrorestriction fragments. *J Clin Microbiol* 1996;34:3190-5.
16. Niederman MS, Ferranti RD, Zeigler A, Merrill WW, Reynolds HY. Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. *Chest* 1984;85:39-44.